Notwithstanding promising clinical results, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant resistance from PBMs. The companies are often erecting limitations to access, including high cost criteria and prior authorization that hinder consumer availability. Market indicate th